Compare AGCO Corporation (AGCO) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AGCO Corporation vs Ginkgo Bioworks Holdings Inc — how do they compare? AGCO Corporation trades at $113.41 (market cap $8.24B), while Ginkgo Bioworks Holdings Inc trades at $8.93 (market cap $610.13M). The key difference: AGCO Corporation is far larger — about 13.5× Ginkgo Bioworks Holdings Inc's market cap, and AGCO Corporation pays a 1.05% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| AGCO | DNA | |
|---|---|---|
Market Cap | $8.24B | $610.13M |
Sector | Industrials | Health |
52-Week High | $140.49 | $16.14 |
52-Week Low | $100.14 | $5.48 |
Enterprise Value | $10.41B | $647.37M |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGCO trades at $113.75, down 2.35% today, with a neutral technical signal and bullish moving averages. The company shows solid fundamentals with a P/E of 11.41 and net income margin of 7.43%, supported by three consecutive earnings beats. Recent news highlights marketing initiatives and fuel efficiency advancements, while cash flow improved to $249.10M in 2025 from negative levels in prior years.
The outlook remains positive with a consensus price target of $147.50, implying 30% upside, though risks include agricultural sector volatility and debt levels. Earnings momentum and valuation discounts present opportunities, but investor sentiment is balanced with equal buy/hold ratings from analysts.
DNA trades at $10.11, down 2.79% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $312.76M on $170.16M revenue in 2025, with negative cash flow and declining revenue projected into 2026. Recent news highlights include Ginkgo Bioworks' pivot to autonomous labs and insider selling activity, while analyst consensus shows a divided outlook with 45% buy ratings.
The outlook remains challenging due to persistent losses and cash burn, though technical strength offers short-term support. Investment opportunity hinges on successful execution of the autonomous lab strategy, while risks include continued negative margins, high cash consumption, and competitive pressures in biotechnology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AGCO Corporation
Agco is a global manufacturer of agricultural equipment. The company has five principal brands: Fendt, Massey Ferguson, Challenger, Valtra, and GSI. Unlike its competitors, Agco's product line extends beyond self-propelled equipment and implements by offering grain handling systems and livestock management solutions. Its products are available through a global dealer network, which includes over 3,200 dealer and distribution locations. Additionally, Agco offers both retail and wholesale financing to customers through its joint venture with Rabobank, a European food and agriculture focused bank.
Read more on AGCO →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
